222 related articles for article (PubMed ID: 22079161)
21. Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Arakawa K; Yuge N; Maehara S
Pharmacol Rep; 2020 Apr; 72(2):443-448. PubMed ID: 32144743
[TBL] [Abstract][Full Text] [Related]
22. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
Dekundy A; Lundblad M; Danysz W; Cenci MA
Behav Brain Res; 2007 Apr; 179(1):76-89. PubMed ID: 17306893
[TBL] [Abstract][Full Text] [Related]
23. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine.
Hansen HH; Andreasen JT; Weikop P; Mirza N; Scheel-Krüger J; Mikkelsen JD
Eur J Pharmacol; 2007 Sep; 570(1-3):77-88. PubMed ID: 17628530
[TBL] [Abstract][Full Text] [Related]
24. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
[TBL] [Abstract][Full Text] [Related]
25. Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Murakami Y; Nishijima H; Nakamura T; Furukawa T; Kinoshita I; Kon T; Suzuki C; Tomiyama M
Neurosci Lett; 2023 May; 806():137248. PubMed ID: 37061023
[TBL] [Abstract][Full Text] [Related]
26. Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain.
Zhang F; Liu S; Jin L; Tang L; Zhao X; Yang T; Wang Y; Huo B; Liu R; Li H
Pharmacology; 2020; 105(7-8):471-476. PubMed ID: 32062659
[TBL] [Abstract][Full Text] [Related]
27. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
28. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
Visanji NP; Millan MJ; Brotchie JM
Exp Neurol; 2006 Nov; 202(1):85-92. PubMed ID: 16814282
[TBL] [Abstract][Full Text] [Related]
29. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
30. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
31. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Zhang H; Ma L; Wang F; Chen J; Zhen X
Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
[TBL] [Abstract][Full Text] [Related]
32. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ; Large CH; Sankar R
Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
[TBL] [Abstract][Full Text] [Related]
33. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
34. Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania.
Redrobe JP; Nielsen AN
Behav Brain Res; 2009 Mar; 198(2):481-5. PubMed ID: 19162078
[TBL] [Abstract][Full Text] [Related]
35. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Koprich JB; Fox SH; Johnston TH; Goodman A; Le Bourdonnec B; Dolle RE; DeHaven RN; DeHaven-Hudkins DL; Little PJ; Brotchie JM
Mov Disord; 2011 Jun; 26(7):1225-33. PubMed ID: 21465551
[TBL] [Abstract][Full Text] [Related]
36. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Pinna A; Fenu S; Morelli M
Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
[TBL] [Abstract][Full Text] [Related]
37. Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias.
Malmlöf T; Rylander D; Alken RG; Schneider F; Svensson TH; Cenci MA; Schilström B
Exp Neurol; 2010 Oct; 225(2):408-15. PubMed ID: 20659451
[TBL] [Abstract][Full Text] [Related]
38. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Pavón N; Martín AB; Mendialdua A; Moratalla R
Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
[TBL] [Abstract][Full Text] [Related]
39. Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization.
Bordia T; Campos C; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2010 Jun; 333(3):929-38. PubMed ID: 20200117
[TBL] [Abstract][Full Text] [Related]
40. Modeling dyskinesia in animal models of Parkinson disease.
Morin N; Jourdain VA; Di Paolo T
Exp Neurol; 2014 Jun; 256():105-16. PubMed ID: 23360802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
